Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Change in Cash: 2018-2024

Historic Change in Cash for Silence Therapeutics (SLN) over the last 7 years, with Dec 2024 value amounting to $52.5 million.

  • Silence Therapeutics' Change in Cash rose 172.43% to $40.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$96.3 million, marking a year-over-year increase of 19.49%. This contributed to the annual value of $52.5 million for FY2024, which is 2866.70% up from last year.
  • Silence Therapeutics' Change in Cash amounted to $52.5 million in FY2024, which was up 2,866.70% from $1.8 million recorded in FY2023.
  • Silence Therapeutics' Change in Cash's 5-year high stood at $63.6 million during FY2021, with a 5-year trough of -$25.0 million in FY2022.
  • Moreover, its 3-year median value for Change in Cash was $1.8 million (2023), whereas its average is $9.8 million.
  • Its Change in Cash has fluctuated over the past 5 years, first crashed by 139.27% in 2022, then skyrocketed by 2,866.70% in 2024.
  • Silence Therapeutics' Change in Cash (MRY) stood at $18.3 million in 2020, then surged by 246.83% to $63.6 million in 2021, then plummeted by 139.27% to -$25.0 million in 2022, then skyrocketed by 107.09% to $1.8 million in 2023, then skyrocketed by 2,866.70% to $52.5 million in 2024.
  • Its Change in Cash was $52.5 million in FY2024, compared to $1.8 million in FY2023 and -$25.0 million in FY2022.